KINETA INC (KA) Stock Price, Quote, News and Overview
NASDAQ:KA - Nasdaq - US49461C1027 - Common Stock - Currency: USD
KA Quote, Performance and Key Statistics
0.5746
-0.25 (-30.69%)
The current stock price of KA is 0.5746 USD. In the past month the price decreased by -17.62%. In the past year, price decreased by -75.02%.
KA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KA
Company Profile
Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. The company is headquartered in Mercer Island, Washington and currently employs 11 full-time employees. The company went IPO on 2016-02-11. The firm has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. The company is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.
Company Info
KINETA INC
7683 Se 27Th Street, Suite 481
Mercer Island WASHINGTON US
Employees: 11
Company Website: https://kinetabio.com/
Phone: 12063780400
KINETA INC / KA FAQ
What is the stock price of KINETA INC today?
The current stock price of KA is 0.5746 USD. The price decreased by -30.69% in the last trading session.
What is the ticker symbol for KINETA INC stock?
The exchange symbol of KINETA INC is KA and it is listed on the Nasdaq exchange.
On which exchange is KA stock listed?
KA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KINETA INC stock?
9 analysts have analysed KA and the average price target is 13.77 USD. This implies a price increase of 2296.45% is expected in the next year compared to the current price of 0.5746. Check the KINETA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KINETA INC worth?
KINETA INC (KA) has a market capitalization of 7.04M USD. This makes KA a Nano Cap stock.
How many employees does KINETA INC have?
KINETA INC (KA) currently has 11 employees.
What are the support and resistance levels for KINETA INC (KA) stock?
KINETA INC (KA) has a resistance level at 0.96. Check the full technical report for a detailed analysis of KA support and resistance levels.
Is KINETA INC (KA) expected to grow?
The Revenue of KINETA INC (KA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the KA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KINETA INC (KA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KA, evaluating the profitability, health, valuation and growth aspects
- KINETA INC (KA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KINETA INC (KA) Sales and EPS estimates to see what analysts future expectations are.
- KINETA INC (KA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KINETA INC (KA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KINETA INC (KA) Stock Chart to make your own analysis
- KINETA INC (KA) Latest news and press-releases to stay up to date.
Does KINETA INC (KA) stock pay dividends?
KA does not pay a dividend.
When does KINETA INC (KA) report earnings?
KINETA INC (KA) will report earnings on 2024-11-01, after the market close.
What is the Price/Earnings (PE) ratio of KINETA INC (KA)?
KINETA INC (KA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.5).
KA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KA. When comparing the yearly performance of all stocks, KA is a bad performer in the overall market: 94.04% of all stocks are doing better.
KA Financial Highlights
Over the last trailing twelve months KA reported a non-GAAP Earnings per Share(EPS) of -1.5. The EPS increased by 68.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1492.21% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to KA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 3.18% and a revenue growth -100% for KA